XOMEXBIO
Founded 2023
About XOMEXBIO
XomeXBio leverages cutting-edge microfluidic technology to address the industrial challenges of miRNA-enhanced small extracellular vesicles (sEVs) production. The platform integrates advanced nano-engineering to enable efficient, scalable, and precise miRNA loading into sEVs without compromising their native properties. Key Features: * Microfluidic Instrumentation & Nano-Chip Mechanoporation: utilizes controlled, temporary squeezing of sEVs as they pass through nano-channels, ensures miRNA loading without altering the vesicle membrane or native biological properties, unlike traditional methods like transfection, sonication, or electroporation. * Scalability: Designed for continuous processing, making it suitable for both small-scale R&D and large-scale clinical manufacturing; Supports high-throughput production with consistent quality; Preservation of sEV Integrity: maintains the natural anti-inflammatory and regenerative properties of sEVs while enhancing their therapeutic potential with miRNA. Applications: * Therapeutics: Enables the development of miRNA-enhanced sEVs for treating degenerative diseases, including osteoarthritis, atopic dermatitis, wound healing, and chronic kidney disease. XomeXBio’s microfluidic technology is a game-changer in the field of advanced therapeutics, offering a scalable, efficient, and precise solution for miRNA-enhanced sEV production.
Company Facts
- Founded: 2023
- Operating status: Operating
- IPO status: Private
- Employees: 1 – 10
- Website: xomexbio.com
- Phone: [email protected]
Canonical: https://fsome.com/organization/xomexbio-8337734 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.